Teva Pharmaceutical Industries (TEVA) Competitors $16.34 +0.05 (+0.31%) Closing price 03:59 PM EasternExtended Trading$16.28 -0.06 (-0.37%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TEVA vs. TAK, ARGX, ONC, BNTX, SMMT, INSM, GMAB, MRNA, RDY, and QGENShould you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Teva Pharmaceutical Industries vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines BioNTech Summit Therapeutics Insmed Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Teva Pharmaceutical Industries (NYSE:TEVA) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Does the media refer more to TEVA or TAK? In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 11 mentions for Teva Pharmaceutical Industries and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.05 beat Teva Pharmaceutical Industries' score of 0.89 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, TEVA or TAK? Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.13-$1.64B-$0.16-102.13Takeda Pharmaceutical$30.09B1.53$712.33M$0.3048.20 Is TEVA or TAK more profitable? Takeda Pharmaceutical has a net margin of 3.20% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Takeda Pharmaceutical 3.20%10.50%5.10% Which has more volatility & risk, TEVA or TAK? Teva Pharmaceutical Industries has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Do insiders & institutionals believe in TEVA or TAK? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer TEVA or TAK? Teva Pharmaceutical Industries presently has a consensus price target of $24.71, indicating a potential upside of 51.25%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTeva Pharmaceutical Industries beats Takeda Pharmaceutical on 10 of the 17 factors compared between the two stocks. Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TEVA vs. The Competition Export to ExcelMetricTeva Pharmaceutical IndustriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$18.68B$3.79B$5.44B$20.70BDividend YieldN/A1.25%4.61%3.67%P/E Ratio-102.139.7729.7528.40Price / Sales1.1312.31449.4856.10Price / Cash4.846.4936.4223.21Price / Book2.744.648.184.33Net Income-$1.64B-$109.62M$3.26B$996.14M7 Day Performance6.24%7.20%1.15%1.93%1 Month Performance-1.86%20.93%2.82%-0.54%1 Year Performance-4.72%39.23%28.41%14.79% Teva Pharmaceutical Industries Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TEVATeva Pharmaceutical Industries2.9437 of 5 stars$16.34+0.3%$24.71+51.3%-2.8%$18.68B$16.54B-102.1336,830Insider TradeTAKTakeda Pharmaceutical2.5448 of 5 stars$14.31-1.2%N/A+4.1%$45.53B$30.09B65.0547,455Gap UpHigh Trading VolumeARGXargenex4.1047 of 5 stars$595.19+0.5%$728.06+22.3%+35.2%$36.43B$2.58B36.721,599News CoveragePositive NewsONCBeOne Medicines1.4547 of 5 stars$294.51+1.0%$327.56+11.2%N/A$32.28B$3.81B-79.1711,000Earnings ReportAnalyst ForecastInsider TradeBNTXBioNTech1.9569 of 5 stars$112.79-2.2%$136.58+21.1%+40.5%$27.11B$2.98B-33.176,772Trending NewsEarnings ReportAnalyst ForecastSMMTSummit Therapeutics1.9978 of 5 stars$27.45-4.3%$34.67+26.3%+198.6%$20.39B$700K-80.73110Positive NewsOptions VolumeINSMInsmed3.7613 of 5 stars$101.75-2.1%$109.20+7.3%+54.0%$19.30B$363.71M-17.101,271Trending NewsEarnings ReportAnalyst ForecastGMABGenmab A/S3.6739 of 5 stars$23.09-1.3%$37.80+63.7%-14.2%$14.81B$3.12B13.122,682Trending NewsEarnings ReportShort Interest ↑Gap DownMRNAModerna4.3204 of 5 stars$33.91-0.7%$46.11+36.0%-67.4%$13.11B$3.24B-3.885,800Earnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories2.3708 of 5 stars$14.71+0.2%$16.95+15.3%-17.7%$12.28B$3.81B22.2827,811News CoveragePositive NewsQGENQiagen3.5514 of 5 stars$51.00-1.5%$49.40-3.1%+11.8%$11.34B$1.98B127.875,765News CoverageEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies TAK Alternatives ARGX Alternatives ONC Alternatives BNTX Alternatives SMMT Alternatives INSM Alternatives GMAB Alternatives MRNA Alternatives RDY Alternatives QGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:TEVA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
